Short answer
Cytek Biosciences, Inc. (CTKB) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Cytek Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 with detailed financial results
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $48.1M, up 6%, with instrument growth in the U.S. and China plus continued service expansion
- Gross margin rose to 59% from 52%, but excluding a one-time tariff refund was 53%
- Net loss widened to $12.2M from $5.6M; adjusted EBITDA declined to a $1.5M loss from $1.3M profit
- Recurring revenue reached $18.5M, representing 35% of trailing-12-month revenue versus 32% previously
- 2026 revenue guidance increased to $207M-$212M, while installed instruments reached 3,933 units with 142 added in Q2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cytek Biosciences, Inc. 8-K filings
Get the next CTKB 8-K as it lands
Follow CTKB for push alerts, or ask the research agent what this filing means.